GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
NeoGenomics, Inc. (NEO) [hlAlert]

Rating:
Buy NEO

NeoGenomics, Inc. (NEO) rated Buy with price target $6 by Dawson James

Posted on: Wednesday,  May 14, 2014  12:00 AM ET by Dawson James

NeoGenomics, Inc. (NASDAQ: NEO)
rated Buy with price target $6 by Dawson James.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories, which is engaged in providing testing services to the pathologists, oncologists, urologists, hospitals, and other laboratories throughout the United States. The testing services offered by the Company?s laboratory include cytogenetics testing, which analyzes human chromosomes; fluorescence In-Situ Hybridization (FISH) testing, which analyzes abnormalities at the chromosomal and gene levels; flow cytometry testing, which analyzes gene expression of specific markers inside cells and on cell surfaces; immunohistochemistry testing, which analyzes the distribution of tumor antigens in specific cell and tissue types, and molecular testing which involves analysis of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) to diagnose and predict the clinical significance of various genetic sequence disorders.

Dawson James Securities is a full service investment firm with deep expertise in healthcare, biotechnology and technology with a staff of over 50 investment professionals ensures our clients stay ahead of the constant changes in the healthcare capital markets. From our widely-respected institutional research, investment banking and high net worth services to our personalized attention for individual accounts, we provide quality service for our clients. We take pride in the quality and depth of our professionals and encourage you to contact us so we can begin serving your financial needs today.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/14/2014 12:00 AM Buy
None
6.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy